CME

Target Audience: The target audience will be orthopaedic surgeons, residents, fellows, and physicians with an interest in orthopaedic treatment.  Athletic trainers, coaches, physical therapists, and clinic administrators/technical staff may also be interested in the program.

Educational Method: Lecture presentations, case studies, and hands-on workshops.

CME Accreditation and Credit Designation: Texas Orthopaedic Association is accredited by the Texas Medical Association to provide continuing medical education for physicians.

The Texas Orthopaedic Association designates AMA PRA Category 1 Credits for the following educational activities:

• Thursday, May 22^nd – Workers’ Compensation Workshop
  7.5 AMA PRA Category 1 Credits
• Friday, May 23^rd – TOA Scientific Session
  6.5 AMA PRA Category 1 Credits
• Saturday, May 24^th – TOA Scientific Session
  4 AMA PRA Category 1 Credits

Physicians should only claim credit commensurate with the extent of their participation in the activity.  The Clinician-Patient Communication Course has been designed for 1 hour ethics and/or professional responsibility.

Objectives:  Upon completion of this activity, participants will be able to learn the results of new research, learn the results of clinical advances, learn how to expand the care provided in your orthopaedic practice, learn about and participate in the activities of the Association, learn about the educational resources of the Association, update basic knowledge and skills, exchange ideas with experts and peers in musculoskeletal care, analyze the health policy trends affecting your patients and practice, assess the latest in orthopaedic equipment and services, provide opportunities to strengthen professional relationships, demonstrate surgical techniques, facilitate evidence based improved outcomes in patients, and promote patient safety.

Disclaimer:  The material presented at the Annual Meeting has been made available by the Texas Orthopaedic Association for educational purposes only.  This material is not intended to represent the only, nor necessarily best, method or procedure appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations.  The TOA disclaims any and all liability for injury or other damages resulting to any individuals attending a session for all claims, which may arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person.  No reproductions of any kind, including still photography, audiotapes and videotapes, may be made of the presentation at the TOA Annual Meeting.  The Association reserves all of its rights to such material, and commercial reproduction is specifically prohibited.

Disclosure:  Each participant in the Annual Meeting has been asked to disclose if he or she has received something of value of a commercial company or institution, which relates directly or indirectly to the subject of their presentation.  The TOA has identified the options to disclose as follows:  research or institutional support has been received; miscellaneous non-income support (e.g. equipment or services); royalties; stock or stock options; or consultant or employee and disclosed nothing of value received.  An indication of the participant’s disclosure appears after his or her name as does the commercial company or institution that provided the support.  The TOA does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation at the meeting.

FDA Statement:  Some drugs or medical devices demonstrated at the Annual Meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only.  The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wished to use in clinical practice.

TOA policy provides that “off label” use of a drug or medical device may be described in the TOA’s CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e. it must be disclosed that the FDA has not cleared the drug or device for the described purpose).  Any drug or medical device is being used “off label” if the described use is not set forth on the product’s approval label.